Janus Kinase Inhibitor Treatment Outcomes in Cutaneous Histiocytosis: A Systematic Review

Cutaneous histiocytoses represents a group of rare skin disease characterized by small brown or erythematous papules, with overlying nodules and crusting. Refractory cases are often treated with immunosuppressive therapy, however many cases still lead to poor treatment outcomes. Here, we review the outcomes of Janus Kinase inhibitors (JAKi), a novel therapy in cutaneous histiocytosis refractory to traditional systemic therapies.

皮肤组织细胞增生症（Cutaneous histiocytoses）是一类罕见皮肤疾病，以小型棕褐色或红斑性丘疹为典型表现，丘疹表面可覆有结节与结痂。针对该病的难治性病例，临床常予以免疫抑制疗法，但多数患者的治疗结局仍不理想。本文综述了Janus激酶抑制剂（Janus Kinase inhibitors, JAKi）这一针对传统系统性治疗无效的皮肤组织细胞增生症新型疗法的临床疗效与转归。